Assignment of weight-based antibody units for four additional serotypes to a human anti-pneumococcal standard reference serum 007sp by Goldblatt, D et al.
Title: Assignment of weight-based antibody units for four additional serotypes to a human anti-pneumococcal 1 
standard reference serum 007sp 2 
  3 
Running Title: Pneumococcal Reference Serum 4 
 5 
Goldblatt D1, McKeen A2, Burbidge P1, McElhiney S2, McLaughlin, L2, Johnson A2, Rauh M3, Giardina PC2 6 
 7 
1 University College London Great Ormond Street Institute of Child Health, London, UK 8 
2 Pfizer Vaccine Research and Development, USA 9 
3 Universitätsklinikum Erlangen, GER  10 
  11 
CVI Accepted Manuscript Posted Online 19 July 2017
Clin. Vaccine Immunol. doi:10.1128/CVI.00194-17
Copyright © 2017 American Society for Microbiology. All Rights Reserved.
 o
n
 July 28, 2017 by UC London Library Services
http://cvi.asm
.org/
D
ow
nloaded from
 
 12 
Corresponding Author: 13 
Professor David Goldblatt,  14 
Professor of Vaccinology and Immunology,  15 
Immunobiology Section,  16 
Great Ormond Street Institute of Child Health  17 
University College London,  18 
30 Guilford Street,  19 
London WC1N 1EH,  20 
United Kingdom.  21 
Direct Telephone:  +44 (0)20 7905 2886,  22 
Fax: +44 (0)20 7905 2882,  23 
Email: d.goldblatt@ucl.ac.uk 24 
 25 
Word count 26 
Abstract: 247 27 
Body: 2529 28 
 29 
  30 
 o
n
 July 28, 2017 by UC London Library Services
http://cvi.asm
.org/
D
ow
nloaded from
 
Abstract  31 
The pneumococcal ELISA reference standard serum, Lot 89SF, has been in use since 1990 and was replaced with 32 
a new reference standard serum, 007sp in 2013. This serum was generated under an FDA-approved clinical 33 
protocol, where 278 adult volunteers were immunized with the 23-valent unconjugated polysaccharide vaccine, 34 
Pneumovax II®, and a unit of blood was obtained twice within 120 days following immunization.  Pooled serum 35 
was prepared from the plasma, filled at 6ml per vial and lyophilised. Five independent laboratories participated 36 
in bridging the serotype specific IgG assignments for 89SF to 007sp to establish equivalent reference values for 37 
13 pneumococcal capsular serotypes (1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) using the WHO reference 38 
ELISA. A subsequent follow up study established equivalent reference values for an additional seven serotypes 39 
(8, 10A, 11A, 12F, 15B, 22F, 33F). In this study three laboratories assigned weight-based IgG concentrations in 40 
mcg/mL of serum to 007sp for four additional serotypes; 2, 9N, 17F and 20A. This study completes the 41 
assignment of serotypes in 89SF to 007sp. In addition, the IgG antibody assignments for a 12 member WHO QC 42 
serum panel were extended to cover the four additional serotypes. Agreement was excellent with a 43 
concordance correlation coefficient (rc) > 0.996 when each laboratory was compared to the assigned values for 44 
the 12 WHO QC sera. The 007sp preparation has replaced 89SF as the pneumococcal reference standard.  45 
Sufficient quantities of 007sp are projected to be available for the next 25 years.  46 
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Introduction 47 
A Streptococcus pneumoniae Human Reference Serum, lot 89SF, greatly facilitated the standardization of ELISA 48 
methodologies during a critical period when the first pneumococcal polysaccharide-conjugate vaccines were 49 
being evaluated for licensure. The standard serum was used in serotype specific ELISAs designed to measure 50 
IgG antibody specific for individual pneumococcal capsular polysaccharides. Serotype specific weight-based 51 
values for IgG, IgA and IgM were originally derived for serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F for 52 
Lot 89SF by Quateart, et al.1. Assignments for the additional serotypes in the 23-valent pneumococcal 53 
polysaccharide vaccine were subsequently bridged from the assignments for the original 11 serotypes2.  Due to 54 
dwindling supplies of 89SF, a new reference standard serum, 007sp, was developed and described in 2011 3. 55 
This serum was generated under an FDA-approved clinical protocol, where 278 adult volunteers were 56 
immunized with the 23-valent unconjugated polysaccharide vaccine, Pneumovax II®, and a unit of blood was 57 
obtained twice within 120 days following immunization.  Pooled serum was prepared from the plasma, filled at 58 
6ml per vial and lyophilised. Five independent laboratories participated in bridging the serotype specific IgG 59 
assignments for 89SF to the new reference serum, 007sp to establish equivalent reference values for 13 60 
pneumococcal capsular serotypes (1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) using the WHO reference 61 
ELISA3 . This serum has replaced 89SF (which is no longer distributed) and been routinely used in pneumococcal 62 
assays around the world for the past several years.  63 
With the ongoing requirement to evaluate Pneumovax II® and the development of additional extended valency 64 
conjugate vaccines, it has been imperative to assign values to 007sp for additional serotypes. In a three-centre 65 
study we recently assigned to 007sp the IgG antibody values in mcg/mL to seven additional pneumococcal 66 
serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F)4.  This report describes the efforts undertaken by the same 67 
three laboratories to establish the serotype specific IgG concentrations for 007sp to the final four remaining 68 
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serotypes in 89SF currently unassigned in 007sp (2, 9N, 17F, and 20A), and to assign values to a set of 12 69 
existing World Health Organisation (WHO) Quality Control (QC) sera for the additional serotypes. 70 
 71 
 72 
Results 73 
To assess the consistency among the laboratories, the mean of the log IgG antibody concentrations of 007sp for 74 
each serotype (2, 9N, 17F, and 20A) was calculated for each laboratory and used to assess the level of 75 
agreement among the laboratories. There was a high level of agreement with the concordance correlation 76 
coefficient rc exceeding 0.95 for all plots. For the same data, the Pearson correlation coefficient was ≥ 0.999, 77 
indicating excellent precision, and the accuracy coefficent (Ca) was ≥ 0.95 in each case. Analysis of variance 78 
(ANOVA) models were used to estimate IgG antibody concentrations for each of the serotypes in 007sp. Final 79 
point estimates and confidence intervals were obtained by back-transforming the estimated log-transformed 80 
concentrations and associated 95% confidence intervals. These estimated IgG antibody concentrations are the 81 
“assigned” values for each serotype (2, 9N, 17F, and 20A) in 007sp and are shown in Table 1. These values were 82 
derived by the double absorption of 007sp with both mono-substituted and di-substituted cell wall 83 
polysaccharide (CPS)5-7, and thus in the future, when used as a reference standard serum, both standard and 84 
unknown test samples should be double absorbed. The IgG antibody concentrations assigned to 007sp 85 
compared to the original values assigned to 89SF are shown in Figure 1.  86 
 87 
Serum IgG antibody concentrations against serotypes 2, 9N, 17F, and 20A were determined for the 12-member 88 
WHO QC serum panel using both 89SF and 007sp as the reference standards. Table 2 presents the assigned 89 
values for the QC serum panel (n≥27 for each estimate) while Figures 2 and 3 display the scatter plots and box 90 
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plots for the four serotypes analyzed. These plots illustrate the agreement of the four estimated assigned IgG 91 
values for 007sp compared to Lot 89SF for each WHO QC serum and serotype.  92 
The scatter plots (Figure 2) show the high degree of agreement and correlation among the calculated (log) IgG 93 
concentrations for the panel of 12 WHO QC sera using 007sp (vertical scale) vs. Lot 89SF (horizontal scale) as 94 
reference standards. A perfect level of agreement would yield a straight line with slope of one and intercept at 95 
zero, and all data points cluster tightly about this line of identity. Laboratories 1 and 3, which both used 96 
automated liquid-handling robotics to perform the assays, showed a slightly lower degree of scatter around the 97 
line of identity compared to Laboratory 2, which used a manual assay process.  The box plots (Figure 3) 98 
illustrate the deviation of the 007sp-based estimates from those obtained using Lot 89SF as reference standard 99 
for the 12 WHO QC sera. The IgG concentrations calculated using 007sp as reference standard are largely within 100 
two fold (1/2 – 2.0) of those calculated using lot 89SF as reference standard.  101 
 102 
Table 3 presents the accuracy coefficient (Ca), Pearson correlation coefficient (r), and concordance correlation 103 
coefficient (rc) which are measures of agreement between pairs of laboratories and between laboratories and 104 
consensus ELISA concentrations for the WHO QC sera.  To form paired data between the labs for these 105 
comparisons, the serotype-specific replicate IgG antibody concentration values generated in each laboratory 106 
were replaced by a single predicted value obtained from a mixed-model analysis of variance. There was an 107 
exceptionally high degree of agreement with all values ≥ 0.99. 108 
 109 
Discussion 110 
In this study, we describe the assignment of IgG antibody concentrations in weight-based microgram per 111 
milliliter units to the human anti-pneumococcal standard reference serum 007sp and a panel of 12 112 
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pneumococcal QC sera for the final four additional serotypes originally calculated and assigned to 89SF. This 113 
new standard was developed in 2009/10 and was required to replace limited stocks of the original standard 114 
serum Lot 89SF.  Assignment for additional serotypes are required as the original standard, Lot 89SF, which had 115 
values assigned for the 23 serotypes in Pneumovax II®, is no longer available (007sp is exclusively distributed via 116 
FDA). However studies evaluating Pneumovax II® are still undertaken and new conjugate vaccines are currently 117 
under development incorporating additional serotypes found in Pneumovax II®, but not in existing PCV’s. 118 
Assignment of the weight-based antibody concentrations to human anti-pneumococcal standard reference 119 
serum 007sp was originally performed for the 13 serotypes represented in currently licensed conjugate 120 
vaccines (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F)3.  Using established laboratories and a well 121 
characterized ELISA procedure 8,9 that was followed by all participating laboratories, it was possible to assign 122 
weight-based units to 007sp by running 007sp alongside a standard curve of 89SF and treating 007sp as the 123 
unknown. Very high levels of agreement between the participating laboratories for the weight-based units of 124 
IgG specific for 13 serotypes in 007sp were achieved.  Having accepted concentration values for an existing 125 
standard has significantly simplified the assignment process. Subsequently we undertook a further assignment 126 
exercise utilizing the expertise of three laboratories. Values (mcg/ml) for IgG specific to seven additional 127 
serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) were assigned to 007sp and the 12 QC sera described above4. 128 
As in the original assignment study, we have now assigned values (mcg/ml) for IgG specific for the final four 129 
serotypes in 89SF that remained unassigned (2, 9N, 17F and 20A). We were able to further validate the values 130 
obtained and the performance of 007sp as a standard during the process of assigning serotype specific IgG 131 
values (mcg/ml) to a panel of 12 WHO QC sera previously prepared from the sera of pneumococcal 132 
polysaccharide vaccinated adults. Concordance was high among laboratories (Table 3) and between results for 133 
laboratories and consensus ELISA concentrations. With the adherence to the uniform application of the WHO 134 
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ELISA9 in the present study, we were able to achieve high levels of precision and accuracy in the values assigned 135 
to the additional four serotypes of 007sp and the WHO QC sera. 136 
ANOVA mixed modeling is a flexible framework that allows estimation of ELISA concentrations for 007sp and 137 
the 12 WHO QC sera for each serotype by laboratory. These models may be used to compare and contrast 138 
results within and among laboratories. Random-effects ANOVA models allowed us to reduce the replicate 139 
measurements to a single predicted value which were then used to measure levels of consistency among the 140 
laboratories. While we were able to estimate serotype-specific concentrations for 007sp through a bridge to 141 
89SF (Table 1), the actual ELISA concentrations for the WHO QC sera used in this study were unknown, so it was 142 
not possible to compare “true” values. The ANOVA mixed model provided a mechanism for estimating 143 
consensus values, which served as assigned values for these sera (Table 2). 144 
Establishing a new reference serum for the pneumococcus was essential for ongoing efforts to evaluate new 145 
pneumococcal vaccines and to maintain the link with the original serology performed as part of the pivotal 146 
efficacy studies conducted prior to licensure. The high degree of agreement between the 007sp-based and lot 147 
89SF-based estimates in the original assignment exercise3 has inspired confidence in the validity of the 007sp 148 
assignments. In this follow on study, a similar high level of agreement has been observed. 149 
The new standard, 007sp, now has assigned values for the 24 pneumococcal serotypes currently contained in 150 
licensed vaccines, is available in large quantities and should provide continuity for the foreseeable future. Its 151 
performance in ELISA suggests that it is unlikely to affect the operation of validated assays currently established 152 
in serology laboratories. Details of how to obtain 007sp and the QC sera are available at 153 
https://www.vaccine.uab.edu/.  154 
  155 
Materials and Methods 156 
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Collection of Human Sera 157 
The collection and processing of sera has been described in detail in a previous manuscript 3. Briefly, 278 158 
volunteers were vaccinated once with Pneumovax II®, and serum collected on two occasions post vaccination. 159 
Serological and virological testing showed sera to be free from Hepatitis B and C virus, syphilis and HIV. Sera 160 
from 262 volunteers were pooled and then aliquoted at 6 ml per vial and lyophilised while sera from the 161 
remaining 16 donors were separately aliquoted to create a new panel of individually calibrated sera for use in 162 
functional assays.  163 
An existing WHO QC serum panel, established by D. Goldblatt (UCL Institute of Child Health) previously by 164 
immunizing adults with pneumococcal polysaccharide vaccine, and distributed by the National Institute for 165 
Biological Standards and Control (NIBSC; Potters Bar, Hertfordshire, United Kingdom), was supplied for 166 
assigning serotype-specific IgG assignments for the 12 QC serum panel members. 167 
Laboratory Methods 168 
Three laboratories participated in the assignment (In alphabetical order: Institute of Child Health, University 169 
College London, London, United Kingdom; Pfizer Vaccine Research and Development, Pearl River, NY; and 170 
Universitätsklinikum Erlangen Kinder- und Jugendklinik, Erlangen, Germany). Two of the three laboratories used 171 
liquid-handling robotics to perform various aspects of the ELISA while the other laboratory performed the 172 
assays by hand. The assignment of weight-based units followed the protocol established for the initial 173 
assignment, which can be found under the reference materials section at http://www.vaccine.uab.edu and 174 
mirrored the protocol used to assign values for an additional seven serotypes4. In the first phase of the study, 175 
serotype-specific IgG antibody assignments for four serotypes (2, 9N, 17F, and 20A) were established by 176 
calibrating Lot 007sp under double absorbent assay conditions against Lot 89SF under single absorbent 177 
conditions using the standardized pneumococcal reference ELISA (the “WHO ELISA”)8,9. The ELISA protocol 178 
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followed by participating laboratories can be found at http://www.vaccine.uab.edu/ELISA%20Protocol.pdf. The 179 
only deviation from the WHO protocol is that double absorption of 007sp with cell wall polysaccharide (CPS)5 180 
was undertaken using two absorbents prepared from un-encapsulated S. pneumoniae mutant strains 181 
incorporating both mono- and di-substituted CPS7,8 rather than CPS and purified 22F capsular polysaccharide.  182 
Lot 89SF had a value assigned for Serogroup 20, the serogroup included in Pneumovax 23®. This sugar has now 183 
been identified as serotype 20A10 so this capsular polysaccharide and nomenclature has been used in this 184 
assignment exercise. Briefly, four independent sets of serial dilutions of lot 007sp (supplied by CBER, FDA) were 185 
made from four independent serum vials. The four sets of eight serial dilutions were run in duplicate as 186 
unknown samples on each ELISA plate in a 10-plate replicate series to generate approximately 40 data points 187 
per serotype for 007sp from each of the participating laboratories.  Each plate also contained seven serial 188 
dilutions of lot 89SF run in duplicate and quality control serum.  The ELISA procedure was carried out for each 189 
serotype, and the raw optical density measurements were sent to Pfizer’s testing laboratories for analysis.  190 
In the second phase of the study, a panel of 12 existing WHO quality QC was assayed and quantified using both 191 
007sp and 89SF as reference standards. Three WHO QC sera, as well as 007sp and 89SF, were run in duplicate 192 
on each ELISA plate yielding up to 10 independently determined QC values for each sample and serotype from 193 
each laboratory over a minimum of 5 days.  The performance of 007sp was assessed by comparing calculated 194 
concentrations using 007sp to those using 89SF as the reference standard.   195 
 196 
Statistical Analysis:  197 
During each phase of the study and the selected repeated assays, there were about 40 determinations of IgG 198 
antibody concentrations for 007sp for each serotype from each laboratory. IgG antibody concentrations were 199 
estimated for the four serotypes using a linear mixed-effects analysis of variance (ANOVA) model. All models 200 
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were fit independently by serotype and included laboratory and batch as random effects. Confidence intervals 201 
(95% CI) were estimated by serotype, accounting for the variance components between the laboratories, 202 
between batches within a laboratory and residual variability. Data were analyzed after (common) log 203 
transformation of ELISA IgG concentrations. The means of the log concentrations for each serotype were 204 
calculated for each laboratory and used to assess agreement and precision among the three laboratories.  205 
Agreement is defined as the closeness of the (log) concentration between two laboratories for each of the four 206 
serotypes and is measured using Lin’s concordance correlation coefficient (rc), which is a combination of Lin’s 207 
coefficient of accuracy (Ca)
11 and Pearson’s correlation coefficient (r).  208 
 209 
Once the four antigen-specific IgG concentration estimates for 007sp were finalized, IgG concentrations were 210 
determined for 12 samples from the WHO QC serum panel. Through the two phases of the study, each 211 
laboratory contributed up to ten IgG concentration estimates for each WHO QC sample for each serotype. The 212 
12 WHO QC samples do not have known ELISA concentrations or assignments for serotypes 2, 9N, 17F and 20A, 213 
and hence, “consensus” ELISA IgG concentration values were estimated using an analysis-of-variance (ANOVA) 214 
mixed-effects model from the present data. Scatter plots and boxplots were employed to assess and evaluate 215 
the ability of the three laboratories to produce consistent estimates of antibody concentrations for each 216 
serotype in 007sp.  217 
 218 
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 Figure Legends: 261 
 262 
Figure 1: Comparison of the original assigned values for four serotypes in 89SF with those assigned to 007sp. 263 
 264 
Figure 2: Scatter plots showing the correlation among the derived concentrations for the panel of 12 WHO QC 265 
sera using 007sp (vertical scale) vs. 89SF (horizontal scale) as reference standards for the four serotypes 266 
analysed (N=>8 for each for the 12 QC serum from each laboratory). 267 
 268 
Figure 3: Box plots illustrating the deviation of the 007sp estimates from those obtained using 89SF for the four 269 
serotypes of the panel of 12 WHO QC sera analysed (N≥8 for each QC serum from each laboratory; Ntotal≥108). 270 
In these plots, the box is defined by the 25th and 75th percentiles of the distribution; the line within the box 271 
represents the median or 50th percentile. Vertical lines extend to the most extreme observation that is less 272 
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than 1.5 times the interquartile range (75th to 25th percentiles), solid circles correspond to individual assay 273 
values which are progressively distant from the bulk of the data. Data above the horizontal line of 1 on the 274 
vertical axis indicates 007sp estimates are greater than estimates using Lot 89SF. On the vertical axis, 2 275 
indicates a point where the 007sp estimate was twice the 89SF estimate. A value of 1/2 indicates the 89SF 276 
estimate was two times the 007sp estimate. Boxes centered on the horizontal line of 1 indicate a good 277 
agreement between the 007sp and 89SF estimates.  278 
 279 
  280 
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 281 
Table 1.  Assigned IgG antibody concentrations (mcg/ml) for 007sp 282 
Type 
89SF ELISA IgG 
concn (mcg/mL) 
007sp ELISA IgG 
concn (mcg/mL) 
95% CI of  007sp 
IgG concn n 
2 12.24 24.63 (21.25, 28.55) 260 
9N 7.77 7.03 (5.52, 8.94) 247 
17F 1.75 8.51 (6.74, 10.73) 253 
20A 8.73 10.47 (8.55, 12.81) 250 
 283 
 284 
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Table 2. Assigned values for 12 pneumococcal WHO QC serum samples as determined with the new pneumococcal reference 285 
standard 007sp 286 
 287 
 
Assigned IgG value in mcg/mL (95% CI) for pneumococcal serotype: 
WHO 
Calibration 
Serum 2 9N 17F 20A 
730 24.14 (21.59, 27.00) 5.43 (4.83, 6.12) 6.72 (6.02, 7.49) 11.55 (10.16, 13.12) 
732 1.21 (1.08, 1.35) 2 (1.78, 2.26) 1.36 (1.22, 1.51) 6.17 (5.43, 7.01) 
736 45.05 (40.16, 50.55) 1.66 (1.48, 1.87) 9.65 (8.65, 10.77) 0.93 (0.82, 1.06) 
746 1.77 (1.58, 1.99) 8.05 (7.16, 9.06) 3.56 (3.19, 3.97) 1.56 (1.37, 1.77) 
754 18.43 (16.45, 20.64) 16.02 (14.23, 18.02) 3.62 (3.25, 4.04) 3.44 (3.03, 3.91) 
758 50.73 (44.88, 57.35) 3.12 (2.77, 3.51) 22.46 (19.98, 25.25) 5.76 (5.07, 6.55) 
760 112.91 (100.64, 126.67) 10.01 (8.89, 11.26) 22.37 (20.05, 24.95) 12.79 (11.26, 14.54) 
762 5.29 (4.72, 5.93) 0.88 (0.78, 0.98) 0.38 (0.34, 0.43) 29.56 (26.04, 33.56) 
768 2.45 (2.19, 2.74) 8.68 (7.71, 9.77) 1.04 (0.93, 1.16) 17.48 (15.38, 19.87) 
770 78.11 (69.62, 87.63) 13.44 (11.94, 15.12) 1.49 (1.34, 1.66) 167.72 (148.24, 189.75) 
772 33.05 (29.41, 37.15) 3.06 (2.72, 3.44) 21.36 (19.11, 23.87) 34.56 (30.45, 39.22) 
774 0.6 (0.53, 0.67) 1.82 (1.62, 2.05) 2.55 (2.29, 2.84) 1.48 (1.30, 1.68) 
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n = ≥27 for each estimate 
 288 
  289 
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Table 3. Comparison of ELISA concentrations between laboratories and laboratory-to-consensus assigned values for WHO QC seraa  290 
 291 
  
Value for Laboratory: 
Laboratories Statistic LAB 1 LAB 2 LAB 3 
LAB 1 (N=48) Accuracy Coef (Ca)
b 1 1 1 
LAB 1 Pearson CC (r)b 1 0.993 0.998 
LAB 1 Concordance CC (rc)
b 1 0.993 0.998 
 
CCC 95% CI 
 
(0.988, 0.996) (0.996, 0.999) 
     
LAB 2 (N=48) Accuracy Coef (Ca)  
1 1 
LAB 2 Pearson CC (r) 
 
1 0.994 
LAB 2 Concordance CC (rc)  
1 0.994 
 
CCC 95% CI 
  
(0.989, 0.997) 
     
LAB 3 (N=48) Accuracy Coef (Ca)   
1 
LAB 3 Pearson CC (r) 
  
1 
LAB 3 Concordance CC (rc)   
1 
 
CCC 95% CI 
   
     
Consensus Value (N=48) Accuracy Coef (Ca) 1 1 1 
 
Pearson CC (r) 0.999 0.997 0.999 
 
Concordance CC (rc) 0.999 0.997 0.999 
  CCC 95% CI (0.998, 0.999) (0.995, 0.999) (0.998, 0.999) 
 292 
a Consensus ELISA (log) concentrations were estimated within a serotype by use of a mixed-effects ANOVA model. Predicted ELISA 293 
(log) concentrations were obtained for each laboratory by sample within a serotype for each of the replicate observations by use of 294 
a mixed-effects ANOVA model. Values in parentheses are 95% confidence intervals. 295 
 296 
b Ca, accuracy coefficient, r, Pearson correlation coefficient, rc, concordance correlation coefficient
  297 
 o
n
 July 28, 2017 by UC London Library Services
http://cvi.asm
.org/
D
ow
nloaded from
 
 o
n
 July 28, 2017 by UC London Library Services
http://cvi.asm
.org/
D
ow
nloaded from
 
 o
n
 July 28, 2017 by UC London Library Services
http://cvi.asm
.org/
D
ow
nloaded from
 
 o
n
 July 28, 2017 by UC London Library Services
http://cvi.asm
.org/
D
ow
nloaded from
 
